SparingVision
Paris, France· Est. 2016
We are a genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments as quickly as possible to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.
Private Company
Total funding raised: $120.1M
About
We are a genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments as quickly as possible to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.
RNA & Gene TherapyViral Technology
Funding History
2Total raised:$120.1M
Series B$75.6MJan 15, 2022
Series A$44.5MJan 15, 2020